Could a popular weight loss drug also curb alcohol cravings? Semaglutide (known by brand names like Wegovy and Ozempic) is widely recognized for helping people lose weight. But now, emerging research suggests this GLP-1 receptor agonist may do much more — including helping people struggling with Alcohol Use Disorder (AUD).
What Is Semaglutide and How Does It Work?
Semaglutide is FDA-approved for managing type 2 diabetes and obesity. It mimics a hormone called GLP-1 (glucagon-like peptide-1), which regulates appetite, insulin, and blood sugar. But beyond those effects, researchers are uncovering its powerful influence on the brain’s reward system — the same part of the brain involved in addiction and cravings.
Can a Weight Loss Drug Treat Alcohol Use Disorder?
The connection became evident as patients taking Semaglutide for weight loss began reporting another unexpected benefit: a significant reduction in alcohol cravings and consumption. Physicians across the country noticed similar patterns, prompting deeper investigation into Semaglutide’s impact on addiction-related behaviors.
What the Science Says: Clinical Trials and Observational Studies
A large Swedish observational study followed over 230,000 individuals diagnosed with Alcohol Use Disorder between 2006 and 2023. Among them, over 6,000 had taken GLP-1 medications like semaglutide. The results were striking: a significantly reduced risk of hospitalization due to alcohol-related issues and other health problems compared to those not using these medications.
A recent clinical trial, published in JAMA Psychiatry, enrolled 48 adults with AUD. Over a 9-week treatment period, participants who received semaglutide not only drank less but also reported reduced cravings and, in some cases, smoked fewer cigarettes.
Semaglutide vs Traditional AUD Medications
Since 1951, only three medications have received FDA approval to treat AUD: disulfiram (Antabuse), naltrexone, and acamprosate. These medications are often underused due to limited effectiveness, side effects, and the stigma associated with addiction treatment.
The potential for semaglutide to outperform these traditional treatments could be a major leap forward — especially when you consider its added benefits for weight loss, metabolic health, and even smoking cessation.
Understanding the Brain’s Reward System
Dr. Lorenzo Leggio, a leading researcher at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), explains that “parts of the brain that drive eating behaviors overlap extensively with the drive to use alcohol or other substances.” That overlap may be the key to why semaglutide works for both.
Off-Label Prescribing: A Growing Trend
With early results being so promising, many physicians have already begun prescribing semaglutide “off-label” to patients with AUD. While this practice is legal and often guided by clinical judgment, more randomized, large-scale trials are needed to secure full FDA approval for this use.
Potential Benefits Beyond Alcohol Reduction
Interestingly, semaglutide has also been associated with decreased cannabis use and cigarette smoking in some patients. These findings suggest GLP-1 medications may one day be used to treat a variety of substance use disorders — not just AUD.
What About Tirzepatide?
Tirzepatide (Zepbound, Monjauro), another GLP-1 medication, is now under study as well. Researchers at Brigham and Women’s Hospital in Boston are currently conducting a clinical trial to evaluate its effects on alcohol cravings and self-reported use. While earlier in the research pipeline, tirzepatide’s dual action on GIP and GLP-1 receptors may hold even greater potential.
Are We Underestimating Semaglutide’s Effectiveness?
One fascinating note: many of the studies so far have used lower doses of semaglutide than what’s commonly prescribed in real-world weight loss regimens. Doctors believe that higher doses — often used to combat stubborn food cravings — might also result in even stronger reductions in alcohol cravings.
A Global Health Need: Why This Matters
Alcohol use is one of the leading modifiable causes of death worldwide and contributes to over 200 health conditions, including liver disease, cancer, and heart disease. Despite this, fewer than 10% of people with AUD receive any form of treatment, and less than 2% get medication-assisted therapy.
If GLP-1 medications like semaglutide can help bridge that treatment gap, the public health implications are massive.
Final Thoughts: A Game-Changer for Addiction Treatment?
As evidence continues to mount, semaglutide may soon be recognized not only as a weight loss and diabetes drug but as a pioneering treatment for addiction.
Its dual ability to reduce physical cravings and address the neurochemical pathways of addiction makes it a standout candidate in the fight against AUD. For now, patients and clinicians alike are watching closely — and hoping this is just the beginning.
Sources & Further Reading:
